Cetero records $3.1 million net loss in April; Abbott and Syngene open new R&D center in India;

 @NesaNFierce: Catalent's renovated fill-finish plant in NC is more in-tune with the company's renewed business focus. Article | Follow @NesaNFierce

> Cetero Research recorded a net loss of $3.1 million in April due in large part of its company restructuring and redoing work for the FDA. Article

> Quintiles has signed licensing agreements that enable the CRO to gain access to electronic medical records data representing 40 million patients. News

> Abbott Laboratories ($ABT) and Syngene opened their state-of-the-art nutrition R&D center in Bangalore, India. It is the first facility of its kind in the country, the companies say. Story

> PacificGMP and Vasgene Therapeutics announced that they have successfully completed the large-scale manufacturing of Vasgene's recombinant fusion protein for use in its Phase I clinical trial. Release

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

WCG is continuing its buyout run after acquiring clinical trial solutions firm Trifecta Clinical.

London-based uMed has raised nearly $4.8 million from U.K. and U.S. VCs to help healthcare providers participate in more clinical studies.

Amgen has teamed up with cloud-based trial solutions firm Reify Health to help boost patients into its drug studies.